Bharat K. Kantharia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bharat K. Kantharia has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
Arti N. Shah
Cardiovascular and Heart Rhythm Consultants, New York, New York; Icahn School of Medicine at Mount Sinai, New York, New York; New York City Health and Hospitals, Elmhurst, Queens, New York
11 shared publicationsBharat Narasimhan
Vanderbilt University Medical Center
9 shared publicationsLingling Wu
East Carolina University Brody School of Medicine, Greenville, North Carolina
8 shared publications- Dominik Linz
Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre , Maastricht
5 shared publications - Xander H. T. Wehrens
Cardiovascular Research Institute, Baylor College of Medicine, Houston, USA
5 shared publications - Jordi Heijman
Department of Cardiology, Cardiovascular Research Institute Maastricht, Faculty of Health, Medicine, and Life Sciences, Maastricht University, Maastricht, The Netherlands
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Elsevier in International Journal of Cardiology
- Vol. 464
Left atrial dimension and new-onset atrial fibrillation in chronic Chagas disease: A competing-risk analysis of the SEARCH-Rio cohort
- 15 September 2026
- Published by Elsevier in International Journal of Cardiology
- Vol. 464
Open AccessLeft atrial dimension and new-onset atrial fibrillation in chronic Chagas disease: A competing-risk analysis of the SEARCH-Rio cohort
- 8 September 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2403-2408
Should Left Atrial Appendage Occlusion Devices Be Routinely Used Instead of Oral Anticoagulants to Prevent Thromboembolic Events, Stroke, and Bleeding for Patients With Non‐Valvular Atrial Fibrillation?
Introduction: Oral anticoagulants (OACs), preferably direct (D)/non‐vitamin K (N) dependent OACs [DOACs/NOACs] are recommended for the management of patients with non‐valvular atrial fibrillation (AF) at risk for thromboembolic events, including stroke. Left atrial appendage occlusion (LAAO) device implantation has been considered for patients who are unsuitable for OACs or prefer not to take them. Herein, we discuss the clinical evidence for routine use of LAAO instead of OACs for patients with AF at risk of thromboembolic events, stroke, and bleeding. Method: From pertinent, recent, randomized clinical trials, the CHAMPION‐AF (Watchman Flx vs. NOAC for Embolic Protection in the Management of Patients with Non‐Valvular Atrial Fibrillation), and CLOSURE‐AF (Catheter‐Based Left Atrial Appendage Closure in Patients with Atrial Fibrillation at High Risk of Stroke and Bleeding as Compared with Best Medical Therapy) were selected for review. Results: As interpreted by the authors of the CHAMPION‐AF trial, LAAOs were considered non‐inferior to NOACs at 3 years. In the CLOSURE‐AF trial, non‐inferiority criteria were not met. For safety, that is, bleeding, LAAO was considered superior in CHAMPION‐AF. We found several points related to both trials that are critical to interpret the results and clinical implications of these trials. These points are particularly related to the interpretation of non‐inferiority trial design, selection bias, combined primary endpoint, bleeding and peri‐procedural bleeding complications, serious adverse events, cross‐over rates, sub‐group analyses, conflicts of interest, and mechanism of stroke. Conclusion: Data from the CHAMPION‐AF and CLOSURE trials do not favor routine and widespread use of LAAO devices in non‐valvular AF patients over use of OACs.
- 8 September 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2403-2408
Should Left Atrial Appendage Occlusion Devices Be Routinely Used Instead of Oral Anticoagulants to Prevent Thromboembolic Events, Stroke, and Bleeding for Patients With Non‐Valvular Atrial Fibrillation?
Introduction: Oral anticoagulants (OACs), preferably direct (D)/non‐vitamin K (N) dependent OACs [DOACs/NOACs] are recommended for the management of patients with non‐valvular atrial fibrillation (AF) at risk for thromboembolic events, including stroke. Left atrial appendage occlusion (LAAO) device implantation has been considered for patients who are unsuitable for OACs or prefer not to take them. Herein, we discuss the clinical evidence for routine use of LAAO instead of OACs for patients with AF at risk of thromboembolic events, stroke, and bleeding. Method: From pertinent, recent, randomized clinical trials, the CHAMPION‐AF (Watchman Flx vs. NOAC for Embolic Protection in the Management of Patients with Non‐Valvular Atrial Fibrillation), and CLOSURE‐AF (Catheter‐Based Left Atrial Appendage Closure in Patients with Atrial Fibrillation at High Risk of Stroke and Bleeding as Compared with Best Medical Therapy) were selected for review. Results: As interpreted by the authors of the CHAMPION‐AF trial, LAAOs were considered non‐inferior to NOACs at 3 years. In the CLOSURE‐AF trial, non‐inferiority criteria were not met. For safety, that is, bleeding, LAAO was considered superior in CHAMPION‐AF. We found several points related to both trials that are critical to interpret the results and clinical implications of these trials. These points are particularly related to the interpretation of non‐inferiority trial design, selection bias, combined primary endpoint, bleeding and peri‐procedural bleeding complications, serious adverse events, cross‐over rates, sub‐group analyses, conflicts of interest, and mechanism of stroke. Conclusion: Data from the CHAMPION‐AF and CLOSURE trials do not favor routine and widespread use of LAAO devices in non‐valvular AF patients over use of OACs.
- Open Access
Nonlinear Dynamics of Left Ventricular Mass Remodeling in Chagas Cardiomyopathy
Left ventricular (LV) mass remodeling in chronic Chagas cardiomyopathy (CCC) is progressive, but whether its dynamics follow nonlinear patterns linked to all-cause mortality remains unexplored. In this SEARCH-Rio substudy, 50 outpatients were followed for 10 years (40 survivors, 10 nonsurvivors). Serial echocardiography provided paired LV mass measurements fitted to the logistic equation x’ = α·x·(1−γ·x), yielding α = 3.952 ± 0.096 and γ = 1.267 ± 0.012, above the complexity threshold (α > 3.57). Lyapunov exponents (LE), computed from consecutive inter patient derivatives, were positive in survivors (+0.349 ± 0.342) and negative in nonsurvivors (−0.459 ± 0.377; p < 0.001), indicating preserved versus lost dynamical complexity, respectively. The fixed-point equilibrium (≈ 179 g) is mathematically unstable for α = 3.952, consistent, but not confirmatory, with sensitive dependence on initial conditions. Complex nonlinear dynamics were independently confirmed at the intra-patient level in a subgroup with extended longitudinal follow-up beyond the initial 10-year period. A Firth penalized regression risk score based on ejection fraction < 51.7% and maximum heart rate < 109 bpm (optimism-corrected AUC = 0.959, bootstrap B = 1,000) showed monotonic mortality gradient and progressively lower LE across strata (Spearman ρ = −0.381, p = 0.003). These findings support nonlinear LV mass remodeling associated with all-cause mortality over the same observation window in CCC; replication in larger cohorts is warranted.
Open AccessNonlinear Dynamics of Left Ventricular Mass Remodeling in Chagas Cardiomyopathy
Left ventricular (LV) mass remodeling in chronic Chagas cardiomyopathy (CCC) is progressive, but whether its dynamics follow nonlinear patterns linked to all-cause mortality remains unexplored. In this SEARCH-Rio substudy, 50 outpatients were followed for 10 years (40 survivors, 10 nonsurvivors). Serial echocardiography provided paired LV mass measurements fitted to the logistic equation x’ = α·x·(1−γ·x), yielding α = 3.952 ± 0.096 and γ = 1.267 ± 0.012, above the complexity threshold (α > 3.57). Lyapunov exponents (LE), computed from consecutive inter patient derivatives, were positive in survivors (+0.349 ± 0.342) and negative in nonsurvivors (−0.459 ± 0.377; p < 0.001), indicating preserved versus lost dynamical complexity, respectively. The fixed-point equilibrium (≈ 179 g) is mathematically unstable for α = 3.952, consistent, but not confirmatory, with sensitive dependence on initial conditions. Complex nonlinear dynamics were independently confirmed at the intra-patient level in a subgroup with extended longitudinal follow-up beyond the initial 10-year period. A Firth penalized regression risk score based on ejection fraction < 51.7% and maximum heart rate < 109 bpm (optimism-corrected AUC = 0.959, bootstrap B = 1,000) showed monotonic mortality gradient and progressively lower LE across strata (Spearman ρ = −0.381, p = 0.003). These findings support nonlinear LV mass remodeling associated with all-cause mortality over the same observation window in CCC; replication in larger cohorts is warranted.
- Open Access
- 11 March 2026
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 15
Atrial Cardiomyopathy and Atrial Fibrillation in Different Heart Failure Substrates
The incidences of AF and heart failure (HF) have been progressively increasing worldwide. These conditions exhibit a strong interdependence, with each exacerbating the other. HF is currently classified based on left ventricular ejection fraction (EF) as HF with reduced, mid-range or preserved EF (HFrEF, HFmrEF or HFpEF, respectively). Atrial cardiomyopathy, also known as atriopathy, involves structural, architectural, contractile, or electrophysiological alterations in the atria, driven by diverse mechanisms stemming from risk factors and comorbidities, including diabetes, hypertension, ischaemic and valvular heart diseases, hypertrophic and dilated cardiomyopathies, as well as various forms of HF. Emerging evidence also implicates infiltrative cardiomyopathies (e.g. cardiac amyloidosis), certain cancers, and chemotherapeutic agents in promoting both AF and HF. This review summarises key basic and translational science findings, along with their potential clinical applications, that connect shared pathophysiological substrates between HF and atrial cardiomyopathy.
- 11 March 2026
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 15
Open AccessAtrial Cardiomyopathy and Atrial Fibrillation in Different Heart Failure Substrates
The incidences of AF and heart failure (HF) have been progressively increasing worldwide. These conditions exhibit a strong interdependence, with each exacerbating the other. HF is currently classified based on left ventricular ejection fraction (EF) as HF with reduced, mid-range or preserved EF (HFrEF, HFmrEF or HFpEF, respectively). Atrial cardiomyopathy, also known as atriopathy, involves structural, architectural, contractile, or electrophysiological alterations in the atria, driven by diverse mechanisms stemming from risk factors and comorbidities, including diabetes, hypertension, ischaemic and valvular heart diseases, hypertrophic and dilated cardiomyopathies, as well as various forms of HF. Emerging evidence also implicates infiltrative cardiomyopathies (e.g. cardiac amyloidosis), certain cancers, and chemotherapeutic agents in promoting both AF and HF. This review summarises key basic and translational science findings, along with their potential clinical applications, that connect shared pathophysiological substrates between HF and atrial cardiomyopathy.
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e042937
Safety of Contemporary Radiation Therapy in Patients With Cardiac Implantable Electronic Devices: Implications for Clinical Practice
Background: Radiation therapy (RT) can cause cardiac implantable electronic device (CIED) malfunction, primarily reset. Given changes in RT and CIED technologies, large observational studies examining malfunction of contemporary CIEDs during modern‐day RT are needed to guide clinical practice. Methods: Electronic medical records of all consecutive patients with CIEDs who underwent RT at a large tertiary cancer center between January 2015 and January 2022 were reviewed. All patients had CIED interrogation before and after completion of RT. Device‐related data and RT‐specific variables were collected. Statistical analyses were performed at the RT course level. Results: Over a period of 7 years, 677 patients (median age, 74 [interquartile range, 67. 8–79.2] years; 72% men) with CIEDs (498 [66%] pacemakers and 254 [34%] implantable cardioverter‐defibrillators) underwent 752 courses of RT (photon, 83.5%; proton, 10.5%; electron, 6%). Only 9 patients (1.3%) underwent CIED relocation before RT. Device malfunction was observed during 8 RT courses (1.1%), primarily soft reset with data loss. All device malfunctions were observed with neutron‐producing radiation (proton and photon >10 MV). CIED type (pacemaker or implantable cardioverter‐defibrillator), magnetic resonance imaging conditional or nonconditional system, and radiation site (thorax or nonthorax) did not show statistical differences between RT courses with reset versus no reset. No transient signal interference or oversensing due to RT was recognized by the CIED. Conclusions: CIED malfunction is a rare complication of contemporary RT, occurring primarily with neutron‐producing radiation, most of CIED malfunction cases are without serious clinical consequences. Transient signal interference and oversensing during RT does not appear to be a clinical concern in contemporary CIEDs.
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e042937
Open AccessSafety of Contemporary Radiation Therapy in Patients With Cardiac Implantable Electronic Devices: Implications for Clinical Practice
Background: Radiation therapy (RT) can cause cardiac implantable electronic device (CIED) malfunction, primarily reset. Given changes in RT and CIED technologies, large observational studies examining malfunction of contemporary CIEDs during modern‐day RT are needed to guide clinical practice. Methods: Electronic medical records of all consecutive patients with CIEDs who underwent RT at a large tertiary cancer center between January 2015 and January 2022 were reviewed. All patients had CIED interrogation before and after completion of RT. Device‐related data and RT‐specific variables were collected. Statistical analyses were performed at the RT course level. Results: Over a period of 7 years, 677 patients (median age, 74 [interquartile range, 67. 8–79.2] years; 72% men) with CIEDs (498 [66%] pacemakers and 254 [34%] implantable cardioverter‐defibrillators) underwent 752 courses of RT (photon, 83.5%; proton, 10.5%; electron, 6%). Only 9 patients (1.3%) underwent CIED relocation before RT. Device malfunction was observed during 8 RT courses (1.1%), primarily soft reset with data loss. All device malfunctions were observed with neutron‐producing radiation (proton and photon >10 MV). CIED type (pacemaker or implantable cardioverter‐defibrillator), magnetic resonance imaging conditional or nonconditional system, and radiation site (thorax or nonthorax) did not show statistical differences between RT courses with reset versus no reset. No transient signal interference or oversensing due to RT was recognized by the CIED. Conclusions: CIED malfunction is a rare complication of contemporary RT, occurring primarily with neutron‐producing radiation, most of CIED malfunction cases are without serious clinical consequences. Transient signal interference and oversensing during RT does not appear to be a clinical concern in contemporary CIEDs.
- Open Access
- 1 September 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Superior vena cava and atrial cardiomyopathy: role of adjunctive superior vena cava isolation ablation in atrial fibrillation
- 1 September 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (9)
Open AccessSuperior vena cava and atrial cardiomyopathy: role of adjunctive superior vena cava isolation ablation in atrial fibrillation
- 27 July 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 256, 161-163
The Psychological Burden of Implantable Cardioverter Defibrillators: Survival at a Price
- 27 July 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 256, 161-163
The Psychological Burden of Implantable Cardioverter Defibrillators: Survival at a Price
- 16 July 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 255, 155-157
Atrial Fibrillation in Transthyretin Amyloid Cardiac Atrial Cardiomyopathy: Mechanisms, Prevalence, and Clinical Implications
- 16 July 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 255, 155-157
Atrial Fibrillation in Transthyretin Amyloid Cardiac Atrial Cardiomyopathy: Mechanisms, Prevalence, and Clinical Implications